Clopidogrel treatment had no discernable impact on the links between dosing frequency and aspirin’s antiplatelet effects.
A multivariate analysis of factors potentially affecting aspirin’s antiplatelet effect found that twice-daily treatment linked with a statistically significant 79% cut in the likelihood of aspirin resistance, compared with once daily. The only other parameter measured with a significant impact on aspirin resistance in this analysis was level of hsCRP. Every 1 mg/L rise in hsCRP linked with a 15% increased rate of resistance.
Dr. Dillinger also reported these findings in a published article (Am. Heart J. 2012;164:600-6)
Dr. Dillinger had no disclosures. Dr. Angiolillo said that he has received honoraria from several drug and device companies including Bristol Myers Squibb, Sanofi-Aventis, Eli Lilly, and others. He has also received research grants from several companies
On Twitter @mitchelzoler